XBP1 and Miyoshi myopathy: Moreover, a low XBP1 spliced/unspliced ratio (sXBP1/uXBP1) has been associated with longer OS and better clinical outcomes in MM patients treated with thalidomide [56], making it a surrogate biomarker for predicting patient response to treatment.